In situ injectable hydrogel encapsulating Mn/NO-based immune nano-activator for prevention of postoperative tumor recurrence
Asian Journal of Pharmaceutical Sciences · 2024-04 · 19 (2) · 100901
DOI: 10.1016/j.ajps.2024.100901 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asian Journal of Pharmaceutical Sciences, 2024-04. Verfasst von Shengnan Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Postoperative tumor recurrence remains a predominant cause of treatment failure. In this study, we developed an in situ injectable hydrogel, termed MPB-NO@DOX + ATRA gel, which was locally formed within the tumor resection cavity. The MPB-NO@DOX + ATRA gel was fabricated by mixing a thrombin solution, a fibrinogen solution containing all-trans retinoic acid (ATRA), and a Mn/NO-based immune nano-activator termed MPB-NO@DOX. ATRA promoted the differentiation of cancer stem cells, inhibited cancer cell migration, and affected the polarization of tumor-associated macrophages. The outer MnO2 shell disintegrated due to its reaction with glutathione and hydrogen peroxide in the cytoplasm to release Mn2+ and produce O2, resulting in the release of doxorubicin (DOX). The released DOX entered the nucleus and destroyed DNA, and the fragmented DNA cooperated with Mn2+ to activate the cGAS-STING pathway and stimulate an anti-tumor immune response. In addition, when MPB-NO@DOX was exposed to 808 nm laser irradiation, the Fe-NO bond was broken to release NO, which downregulated the expression of PD-L1 on the surface of tumor cells and reversed the immunosuppressive tumor microenvironment. In conclusion, the MPB-NO@DOX + ATRA gel exhibited excellent anti-tumor efficacy. The results of this study demonstrated the great potential of in situ injectable hydrogels in preventing postoperative tumor recurrence.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, China.
- School of Pharmaceutical Sciences, Henan Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases, Zhengzhou University, Zhengzhou 450001, China.
- Center for Quantitative Biology, Peking University, Beijing 100871, China.
- School of Pharmaceutical Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, China.
- Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing 400030, China.
- School of Pharmaceutical Sciences, Henan University, Zhengzhou 450046, China.
Zitieren
APA
Huang, S., Zhou, C., Song, C., Zhu, X., Miao, M., Li, C., Duan, S., & Hu, Y. (2024). In situ injectable hydrogel encapsulating Mn/NO-based immune nano-activator for prevention of postoperative tumor recurrence. Asian Journal of Pharmaceutical Sciences, 19(2), 100901. https://doi.org/10.1016/j.ajps.2024.100901
Vancouver
Huang S, Zhou C, Song C, Zhu X, Miao M, Li C, et al. In situ injectable hydrogel encapsulating Mn/NO-based immune nano-activator for prevention of postoperative tumor recurrence. Asian Journal of Pharmaceutical Sciences. 2024;19(2):100901. doi:10.1016/j.ajps.2024.100901
BibTeX
@article{Huang2024,
author = {Huang, Shengnan and Zhou, Chenyang and Song, Chengzhi and Zhu, Xiali and Miao, Mingsan and Li, Chunming and Duan, Shaofeng and Hu, Yurong},
title = {In situ injectable hydrogel encapsulating Mn/NO-based immune nano-activator for prevention of postoperative tumor recurrence},
journal = {Asian Journal of Pharmaceutical Sciences},
year = {2024},
volume = {19},
number = {2},
pages = {100901},
doi = {10.1016/j.ajps.2024.100901}
}
EUVIMED